Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

NCT07473973 is registered in ClinicalTrials.gov with Inozyme Pharma as lead sponsor.

NCT NCT07473973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07473973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Lead sponsor
Inozyme Pharma
Phase
Phase 3
Overall status
Terminated
Start date
March 26, 2025
Completion date
August 31, 2026
Enrollment
2 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal recessive hypophosphatemic rickets, ectonucleotide pyrophosphatase/phosphodiesterase1 deficiency, generalized arterial calcification of infancy 1